Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901

NCT04396457 is registered in ClinicalTrials.gov with National Hospital Organization Nagoya Medical Center as lead sponsor.

NCT NCT04396457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04396457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901
Lead sponsor
National Hospital Organization Nagoya Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
May 25, 2020
Completion date
November 30, 2024
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, lung, non-squamous non-small-cell lung cancer